{
  "id": 9546247,
  "title": "Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development",
  "url": "https://urgent.news/2026/09/24/satellos-announces-fda-clearance-of-ind-application-for-forazapadin",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T11:07:26.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/satellos-announces-fda-clearance-of-ind-application-for-forazapadin-in-facioscapulohumeral-muscular-dystrophy-fshd-and-a-partnership-with-fshd-canada-foundation-providing-non-dilutive-financing-to-s"
  },
  "original_language": "en",
  "account": null,
  "summary": "FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical need FSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the clinical development of forazapadin in FSHD Phase 2 study in FSHD expected to begin in Q4 2026 TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}